lower schreef op 27 januari 2016 14:48:
[...]
Koersdoelen zijn opgbouwd uit.
-Waarde van het bedrijf: intellectueel eigendom, contracten, personeel, gebouwen.
-Omzet/Winstgevendheid
-Mogelijke toekomstige inkomsten
Roth hield en houdt nog rekening met inkomsten uit pancreatitis en dat vind ik ridicuul.
SUMMARY
We are also making revisions to our NPV model, reducing our U.S. peak sales for the acute HAE indication to $50 million from $160 million. This results in a $0.13 decrease in our NPV. Given the modest market penetration for Ruconest thus far and until we see evidence to contrary, we are making changes to our peak sales estimates. We are reducing peak sales for the prophylactic HAE indication to $200 million from $475 million, resulting in a $0.83 decrease in our NPV. We are also reducing peak sales of the pancreatitis indication to $200 million from $300 million, reflecting a decrease of $0.19. We are not assigning any value to the ongoing R&D stage programs for Fabry and Pompe diseases. We thus arrive at a NPV of $1.84 which still reflects a significant upside compared to the $0.38 share price at last close (10/27/15).
roth2.bluematrix.com/sellside/EmailDo...De waarderingsmodellen per analyst verschillen nog al. Ik zou meer detail van de opbouw van het advies willen zien.
Alle koersdoelen op een rij:
De link naar Firt Berlin update 1,50 euro
www.pharming.com/wp-content/uploads/2...KBC morning note; 0,50 euro
www.pharming.com/wp-content/uploads/2...Roth; 1,84 dollar is 1,71 euro (oanda 7 januari 2016)
www.pharming.com/wp-content/uploads/2...Stifel; 0,88 euro
www.pharming.com/wp-content/uploads/2...Gemiddeld: 1,1475 euro